Every acquisition needs a thesis — a clear, specific explanation of what value the deal creates and why it creates more value in combination than either organization would create independently. Acquisitions that proceed without a clear thesis tend to destroy value, not because M&A is inherently risky, but because the integration decisions, retention priorities, and performance benchmarks that follow from a clear thesis are unavailable when the thesis has not been articulated.

The taxonomy of acquisition rationales is well-established. Understanding which rationale applies to a given deal is the first discipline of M&A strategy.

1. Deepening Market Position

A position-deepening acquisition strengthens the firm’s existing standing within a current market or customer segment. The strategic logic is competitive: by adding capabilities, technology, or talent that reinforce current positioning, the firm raises the barrier to competitive displacement.

The most common form in life sciences is a technology platform acquisition — acquiring a firm whose technology, when combined with the acquirer’s existing capabilities, creates a more complete or more differentiated offering. The value is in the combined capability set, not in either component independently.

This rationale also describes acquisitions designed to “expand the moat”: acquiring assets that increase the cost or difficulty for competitors to displace the firm. This might be an IP portfolio, a clinical data set, a key customer relationship, or a manufacturing capability that would be difficult for a competitor to replicate organically.

2. Gap Filling

A gap-filling acquisition addresses a specific deficiency in the firm’s portfolio, capability profile, or market coverage. Unlike position-deepening, which reinforces existing strengths, gap-filling addresses documented weaknesses.

Gap-filling acquisitions are typically smaller and faster to execute than position-deepening deals. The thesis is operational: we need this capability faster than we can build it. The integration approach is correspondingly more absorbed than autonomous — the acquired capability is folded into existing operations rather than maintained as a separate entity.

In life sciences, common gap-filling targets include regulatory capabilities the firm lacks, quality systems that would take years to build organically, specific therapeutic area expertise, or market access relationships in geographies or customer segments the firm has not previously reached.

3. Market or Customer Access

An access acquisition is about reach: acquiring a business because of who it sells to, not primarily what it sells. The acquired firm’s customer base, distribution network, or market relationships become the strategic asset.

This rationale is particularly compelling in life sciences when the target market has high relationship barriers — where procurement decisions are relationship-dependent and new entrants cannot easily cold-call their way to commercial presence. Acquiring a firm with established relationships in a target segment can compress years of commercial development into a single transaction.

The risk in access acquisitions is that the customer relationships being acquired are personal rather than institutional — they belong to individuals who may leave during or after the integration. Diligence and retention planning around key relationship owners is essential.

4. Technology Acquisition

A pure technology acquisition acquires rights to specific technologies — IP, patents, proprietary processes, or data assets — without necessarily requiring the full organizational infrastructure of the target. These transactions are often smaller, faster, and structurally different from operating company acquisitions.

Technology acquisitions frequently begin as licensing relationships. When the licensed technology proves sufficiently strategic — because it underpins a product, process, or capability the firm needs to own rather than license — the relationship evolves into an acquisition.

5. Cost Structure Improvement

A cost-structure acquisition targets operational efficiency: the acquired company has a more cost-effective production model, distribution infrastructure, or service delivery capability that, when combined with the acquirer’s scale and reach, reduces the combined cost base.

In life sciences, cost-structure logic often drives consolidation in CDMO and CRO markets, where scale advantages are real and operational leverage is a genuine source of value.

Deal Screening Criteria

Regardless of acquisition rationale, a consistent set of screening criteria reduces the risk of pursuing deals that look strategically attractive but carry structural problems.